Treatment approaches aim to restore or mimic p53's function in cells where it has gone awry. For example, scientists have developed small molecules that can bind to mutant p53 and stabilize its ...

Another key discovery was a previously unnoticed p53 mutation (A276P) found in a subset of hTERT-RPE1 cells. This mutation weakened p53’s ability to regulate certain genes but did not affect its ...

Another key discovery was a previously unnoticed p53 mutation (A276P) found in a subset of hTERT-RPE1 cells. This mutation weakened p53's ability to regulate certain genes but did not affect its ...

When analyzing the p53 sequence, she noticed that it looked similar to many other known transcription factors. “At the time, my first hypothesis was it was a transcriptional repressor,” Lozano ...

New Drug Research & Development Co. Ltd. has disclosed cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers reported to be useful for the treatment of cancer.

In lab experiments, the researchers found that navtemadlin was one of the best drugs at killing glioblastoma cells with intact, non-mutant p53. The work appears in Science Translational Medicine.

It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman ...